Scrip
FDA panel recommends Recordati's carglumic acid for rare disease
14 January 2010
Daniel Moskowitz
The US FDA's endocrinologic and metabolic drugs advisory committee on January 13 voted unanimously to recommend that the agency approve
Recordati's carglumic acid for the treatment of hyperammonaemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS).
Such total agreement...
Please Login to read the full article.
14 January 2010
Daniel Moskowitz
Such total agreement...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
